Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate Deflects Currency Crush Through Oral Care Sales, Price Hikes

This article was originally published in The Tan Sheet

Executive Summary

Price increases in some regions are crucial to its earnings while Colgate also looks to oral care product launches as sales drivers. With an oral care business that is “one of the few remaining category killers,” the firm could create more value by divesting its home care and pet product businesses, an analyst says.

You may also be interested in...



North America Anchors Colgate As Currency Headwinds Continue Abroad

Innovation across categories helped make Colgate's North American business its star segment in the second quarter, rising 1.6% to $793m on strong oral care sales, while the firm’s international business remains impacted negatively by currency headwinds.

North America Anchors Colgate As Currency Headwinds Continue Abroad

Innovation across categories helped make Colgate's North American business its star segment in the second quarter, rising 1.6% to $793m on strong oral care sales, while the firm’s international business remains impacted negatively by currency headwinds.

Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel